YOO, Jinsang,유진상,KIM, Do Yun,김도윤,CHOI, Jinhee,최진희,LEE, Weon Sup,이원섭,SHIM, Sang Ryeol,심상렬,YOO, Jin San,유진산,KIM, Sung-Woo,김성우,KIM, Yeun Ju,김연주,JEON, Mi Ae,전미애,BYUN, Sang Soon,변상순,LEE, Youngae,이영애,PARK,
申请号：
KRKR2014/009697
公开号：
WO2016/060297A1
申请日:
2014.10.16
申请国别(地区):
WO
年份:
2016
代理人:
摘要：
The present invention relates to a dual-target antibody having a binding ability to vascular endothelial growth factor receptor-2 (VEGFR-2) and mesenchymal epithelial transition factor (c-Met) and, more specifically, to a dual-target antibody having a binding ability to VEGFR-2 and c-Met, a method for producing the dual-target antibody, and a pharmaceutical composition containing the dual-target antibody, wherein the dual-target antibody comprises a VEGFR-2 neutralizing antibody, which has a light chain variable region with an amino acid sequence represented by SEQ ID NO: 1 and a heavy chain variable region represented by SEQ ID NO: 2, and a C-met neutralizing peptide represented by SEQ ID NO: 3 or 4, which is linked to the terminal of the light chain variable region or the heavy chain variable region of the VEGFR-2 neutralizing antibody. The dual-target antibody according to the present invention simultaneously neutralizes two targets involved in angiogenesis and cancer cell proliferation, and thus exhibits an excellent neutralizing ability compared with existing single target antibodies and is very effective in the treatment of cancer. In addition, it can be expected that c-Met neutralizing active domains, which were not previously easy to produce, can be mass-produced.La présente invention concerne un anticorps à double cible présentant une aptitude à la liaison au récepteur 2 du facteur de croissance de lendothélium vasculaire (VEGFR-2) et au facteur de transition épithélio-mésenchymateux (c-Met) et, plus particulièrement, un anticorps à double cible présentant une aptitude à la liaison à VEGFR-2 et à c-Met, un procédé de production de lanticorps à double cible et une composition pharmaceutique contenant lanticorps à double cible, lanticorps à double cible comprenant un anticorps neutralisant le VEGFR-2, qui présente une région variable de chaîne légère présentant une séquence dacides aminés représentée par la séquence SEQ ID NO : 1 et une région variable de cha
